Sign in
CompletedPhase 2

A Randomized Double-Blind Clinical Study of Intracavernosal OnabotulinumtoxinA Injection in Patients With Erectile Dysfunction Refractory to Phosphodiesterase-5 Inhibitors

Key facts

Who runs it
Clinica Universidad de Navarra, Universidad de Navarra
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
114 people enrolled
Started
25 Nov 2024
Ended
2 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • OnabotulinumtoxinA (Botox ®) Injections
  • Saline (0.9% NaCl)
Record updated
22 September 2026

Who can take part

Age
30 years and older
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients diagnosed with erectile dysfunction (ED) with an inadequate response to phosphodiesterase type 5 inhibitors (PDE5 inhibitors) or to intracavernosal injections with Caverject or Bimix/Trimix (IIEF-15 questionnaire score ≤12)
  • Patients aged 30 years or older
  • Patients who have provided informed consent to participate in the study
  • Patients who, in the investigator's opinion, are able to comply with all clinical trial requirements
  • Patients who agree to attend follow-up visits and undergo the required assessments

Who cannot take part

  • Patients who underwent robotic radical prostatectomy less than 6 months prior to study enrollment
  • Severe infections or diseases, or hepatic, renal, or bone marrow insufficiency, that, in the investigator's opinion, contraindicate participation in the study
  • Known hypersensitivity to onabotulinumtoxinA (BoNT-A)
  • Patients with a known history of neurogenic injury
  • Patients with a history of radiation therapy
  • Patients with a known psychiatric disorder
  • Patients younger than 30 years
  • Patients who do not consent to participate in the study
  • Patients with anatomical abnormalities of the penis
  • Patients who do not agree to, or are unable to commit to, attending the scheduled follow-up visits

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the clinical efficacy of intracavernosal treatment with onabotulinumtoxinA (Botox) in 114 men aged 30 years or older with erectile dysfunction who have not responded to first-line oral pharmacological treatment.

Read full original descriptionShow less

For this purpose, the effects of onabotulinumtoxinA are compared with those of a placebo consisting of an intracavernosal injection of physiological saline. The study is patient-blinded.

Participants in the experimental group receive 100 U of onabotulinumtoxinA diluted in 1 mL of physiological saline, while participants in the control group receive 1 mL of physiological saline.

The 2 groups in the trial

  • OnabotulinumtoxinA (Botox) 100 UTreatment being tested

    Participants receive an intracavernosal injection of 100 U of onabotulinumtoxinA (Botox) diluted in 1 mL of physiological saline.

    Treatment: OnabotulinumtoxinA (Botox ®) Injections

  • Placebo (Normal Saline)Placebo, for comparison

    Participants receive an intracavernosal injection of 1 mL of physiological saline as placebo.

    Treatment: Saline (0.9% NaCl)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 September 2026